JY BioMed’s GDT Platform Published in International Journal; Secures US$38M Licensing and Expands into Nasdaq Cell Therapy Ecosystem

JY BioMed (JY BioMed Co., Ltd.) today announced a major advancement in its proprietary gamma delta T cell (GDT) immunotherapy platform. The research has been published in the international scientific journal Immunobiology, demonstrating significant anti-tumor activity in hepatocellular carcinoma (HCC) models, as well as synergistic effects when combined with immune checkpoint inhibitors (PD-L1 blockade).

This breakthrough not only introduces a potential new therapeutic approach for difficult-to-treat liver cancer, but also highlights JY BioMed’s capabilities in advancing translational cell therapy.

Technology Core:

Overcoming Tumor Heterogeneity with Off-the-Shelf Potential

The study was led by JY BioMed in collaboration with Taipei Medical University (TMU) and its affiliated medical system, providing both in vitro and in vivo validation.

Compared to conventional T cell therapies, gamma delta T cells possess MHC-independent tumor recognition, enabling direct targeting of cancer cells and overcoming key challenges such as tumor heterogeneity and immune evasion.

The data demonstrated that unmodified gamma delta T cells exhibit strong, dose-dependent cytotoxicity in both in vitro and in vivo models. Furthermore, the study revealed that blocking the PD-L1/PD-1 axis significantly enhances cytotoxic activity, supporting future combination therapy strategies.

From a safety and manufacturing perspective, the therapy showed no significant systemic toxicity in animal models and presents strong potential as an off-the-shelf (allogeneic) cell therapy. JY BioMed has also completed the submission of a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA), establishing a critical regulatory foundation for future clinical development and global collaboration.

Commercial Strategy:

Cross-Border Licensing and Capital Market Synergy

JY BioMed has demonstrated strong commercial traction by licensing its gamma delta T cell technology to international biotech company SL Bio for the development of therapies targeting brain cancer and pancreatic cancer, two areas with high unmet medical need. The total licensing deal value reaches US$38 million.

Market observers note that SL Bio has filed with the U.S. Securities and Exchange Commission (SEC) for a planned Nasdaq listing under the name SL Science Holding Limited (ticker: SLBT), with an enterprise valuation of US$5.568 billion. As JY BioMed’s technology serves as one of its core assets, the progression of SL Bio’s listing further underscores the global market potential of the GDT platform.

Leadership:

Integration of Capital Markets, Clinical Development, and Industrial Governance

JY BioMed’s leadership team brings together extensive experience across international capital markets, clinical development, and industrial policy.

Founder and Chairman Dr. Ethan Shen is also the Founder, Chairman, and CEO of Nasdaq-listed YD Bio (ticker: YDES).

Chief Medical Officer Dr. Benjamin Zhang concurrently serves in a senior medical leadership role at YD Bio.

In addition, CEO Dr. Adam Chen, former Director-General of the Hsinchu Science Park Bureau, contributes deep expertise in industrial policy, technology sector management, and strategic resource integration.

Market analysts believe this combination of leadership experience positions JY BioMed to effectively scale its innovations globally and accelerate its international expansion.

Outlook

JY BioMed stated that it will continue advancing the clinical development of its gamma delta T cell therapy while actively exploring combination strategies with immune checkpoint inhibitors.

The company is also expanding its technology portfolio to include ADC platforms, stem cell therapies, and exosome-based technologies, with the goal of building a diversified and globally competitive biotechnology platform.

Selected Media Coverage

Commercial Times: https://www.ctee.com.tw/news/20260409702055-431205